ER4 fundamentals
An in-depth look to EMERGENT BIOSOLUTIONS INC operating, investing, and financing activities
ER4 free cash flow for Q1 24 is -68.03 M EUR. For 2023, ER4 free cash flow was -233.66 M EUR and operating cash flow was -186.91 M EUR.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM